- Three recent independent in-vitro studies show that ADG20 has neutralization activity against Omicron.
- ADG20 being explored in the phase 2/3 STAMP and EVADE studies for treatment and prevention of COVID-19, respectively. Studies paused for time being while protocols are amended for higher dosing.
- ADG10 and Pan-CoV are additional treatments being developed in the pipeline for Covid-19. In addition, ability to tap into library with 100 monoclonal antibodies against Covid-19.
- Adagio hopes to use its expertise and technology to also develop a preventative seasonal and pandemic influenza treatment.
For further details see:
Adagio: A COVID-19 Play With Big Potential On Possible Treatment And Prevention